Daisuke Maki is Overseas business development director from J-Pharma. He has more than twenty years of pharmaceutical industry experience with a proven track record in R&D and business development strategy. His current role is responsible for development of clinical stage small molecular JPH203 and OKY-034 in the US.
He started his carrier as a reserch scientist at Chugai Pharmaceutical. He was involved in oncology department to focus discovery of novel anti-cancer agent. After five years of oncolgy reserach he move to the proess development of biologics. His focus was design samll scale of therapeutic antibody production. He gained knowlege of both upstream and downstream of therapeutic antibody production during his five years in CMC department. Last ten years he worked as business development responsible for search and evelution, license-in and license-out activities. He also acommplished seven divestures of establishd products to third party with Roche partnering.